KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Receivables: 2011-2025

Historic Receivables for Supernus Pharmaceuticals (SUPN) over the last 13 years, with Sep 2025 value amounting to $177.6 million.

  • Supernus Pharmaceuticals' Receivables rose 22.11% to $177.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $615.5 million, marking a year-over-year increase of 4.36%. This contributed to the annual value of $146.1 million for FY2024, which is 1.33% up from last year.
  • Supernus Pharmaceuticals' Receivables amounted to $177.6 million in Q3 2025, which was up 21.42% from $146.2 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' Receivables' 5-year high stood at $177.6 million during Q3 2025, with a 5-year trough of $127.1 million in Q1 2021.
  • In the last 3 years, Supernus Pharmaceuticals' Receivables had a median value of $145.6 million in 2025 and averaged $147.9 million.
  • Its Receivables has fluctuated over the past 5 years, first increased by 22.75% in 2022, then declined by 13.61% in 2023.
  • Quarterly analysis of 5 years shows Supernus Pharmaceuticals' Receivables stood at $148.9 million in 2021, then rose by 11.12% to $165.5 million in 2022, then decreased by 12.90% to $144.2 million in 2023, then grew by 1.33% to $146.1 million in 2024, then increased by 22.11% to $177.6 million in 2025.
  • Its Receivables stands at $177.6 million for Q3 2025, versus $146.2 million for Q2 2025 and $145.6 million for Q1 2025.